Recursion Pharmaceuticals, Inc.
NASDAQRXRX short interest utilization falls to 96.19%, down from 100% peaks in late April, as cost to borrow eases to 4.23% from 13.37% mid-month despite persistent 33% short interest of float.
Snapshot as of 6 May 2026
No long-form analysis yet for RXRX. Pulse alerts and the live data picture are available on ORTEX.
Open RXRX on ORTEX →Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RXRX — free to start on ORTEX.
Sign up for free →Open RXRX on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live RXRX data →